192 results about "Cellular functions" patented technology

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention relates to the field and discloses application of terahertz waves or intermediate infrared in preparation of adoptive T lymphocytes. The Terahertz wave or mid-infrared modulation technology is utilized to specifically regulate and control the functions of the T cells in a flowing irradiation mode, and the functions of the T cells from different sources are enhanced under the conditions that no medicine is used and no exogenous gene is introduced. Terahertz wave or mid-infrared stimulation is applied to the T cells in a flowing irradiation mode, specific terahertz wave or mid-infrared frequency for remarkably enhancing the functions of the T cells is determined in a frequency screening mode, and after the optimal irradiation frequency is determined, the T cells with the most remarkable function improvement are further input back into a donor. The T cells stimulated by terahertz waves or mid-infrared rays can play a powerful immune function in a tumor microenvironment so as to inhibit further development of tumors.

The present application relates to the technical field of cell function detection, and particularly relates to a method for evaluating cell function of HL-60 in monocyte activation test. The method comprises the following steps: (1) preparing HL-60 cell suspension; (2) stimulating with pyrogen; (3) quantifying total protein; (4) detecting by Western blotting; and (5) evaluating cell function. The method is based on Western blotting technology, and combines statistical analysis to realize objective and quantitative determination of the core functional index of the ability of synthesizing IL-6 protein under pyrogen stimulation, can accurately identify cells with pyrogen response function defects, provides clear experimental reference for selection of HL-60 cell generations, can pre-screen qualified cells, reduces pyrogen detection deviation caused by unqualified cell function and improper generations from the source, and effectively improves the reliability and repeatability of pyrogen detection results.

Provided are multi-wavelength phototherapy devices, systems and methods for the treatment of a disorder or disease, including multi-wavelength low level light therapy (“PBM”), in particular to multi-wavelength PBM and other phototherapy systems and methods for improving functionality in and / or restoring functionality to a cell and / or tissue through the coordinated and targeted delivery to the cell or tissue of two or more doses of light having distinct wavelengths, wherein the two or more doses of light, when delivered in a coordinated fashion, can stimulate the activity of two or more light sensitive factors that, when activated, provide and / or enhance a desired target cell functionality. Ophthalmic phototherapy devices, systems, and treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The devices include a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

A mitochondrial transplantation system includes a mitochondrial and an apoptosis vesicular membrane, the mitochondrial being carried within the apoptosis vesicular membrane. When a system composed of mitochondria and apoptosis vesicles acts on endothelial cells, the targeting and efficiency of mitochondria transplantation are improved, mitochondria autophagy is generated, mitochondria autophagy is reactivated to remove damaged mitochondria of the endothelial cells, the removal of damaged mitochondria is promoted, and the cell functions of the damaged endothelial cells of mitochondria are recovered. The wound healing is favorably promoted. A system composed of mitochondria and apoptosis vesicle membrane is used as an active component to prepare a drug or a medical device for promoting wound healing.

The invention discloses an application of ametinib in preparation of a medicine for treating liver cancer, belongs to the technical field of new application of medicines, and verifies the potential of third generation EGFR-TKI ametinib in inhibiting liver cancer progression in vivo and in vitro, and cell function experiments prove that ametinib can effectively inhibit proliferation, migration and invasion ability of liver cancer cells; the exact type of ametinib for inducing liver cancer cell death is determined, and ametinib inhibits survival and proliferation of liver cancer cells by activating autophagy and inducing ferroptosis; the application proves that autophagy activated by the ametinib can promote the occurrence of ferroptosis by regulating and controlling the degradation of GPX4 (glutathione peroxidase 4) and the accumulation of reactive oxygen species (ROS), and the ametinib inhibits the progress of liver cancer by inducing autophagy-dependent ferroptosis, so that the ametinib is used for preparing the medicine for treating liver cancer.

The present invention relates to compositions and methods for subpopulation-specific modulation of cell function and for treating repeat expansion disorders comprising genetic, degenerative, neurological and cellular diseases, including immune disorders. Also provided are research kits for subpopulation-specific modulation of protein activity and the corresponding potential to discover novel therapeutic compositions. More specifically, the disclosed compositions and methods selectively up- or downregulate at least a first population of a cellular protein or therapeutic target with minimal or negligible effect on the activity of at least a second population of the cellular protein or therapeutic target.

The invention relates to the technical field of functional reconstruction of functional beta cells of diabetic patients, in particular to a design method and device for functional reconstruction of beta cells based on single-cell multi-omics and a development potential energy field, and is suitable for accurate design and verification of a functional beta cell regeneration treatment scheme of the diabetic patients. According to the method and the device disclosed by the invention, efficient design and verification of a personalized beta cell function reconstruction scheme are realized by integrating single-cell multi-omics data, an embryonic development mechanism and an optimal control theory.

This invention provides a multifunctional nanodelivery system integrating gene delivery and CT tracking. The multifunctional nanodelivery system includes a gene delivery vector and an HGF plasmid gene loaded on the gene delivery vector; the gene delivery vector comprises gold nanoparticles coated with protamine sulfate. The gene delivery vector AuPS provided by this invention has excellent cell membrane transport and nuclear localization capabilities, enabling the HGF plasmid gene to efficiently enter cells and be expressed in the nucleus. The multifunctional nanodelivery system provided by this invention can be used for cell function regulation and tracking of therapeutic cells such as stem cells.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

The invention discloses a living body screening method of a high-throughput addiction inhibitor, which comprises the following steps: acquiring addictive nematodes with a plurality of addiction behavioral phenotypes; applying different addiction inhibitors to the addictive nematodes; the screening of the addiction inhibitors is realized according to the inhibition efficacy of the addiction inhibitors on the addiction behavioral phenotypes of the addiction nematodes, and based on the steps, the drug screening of the addiction inhibitors can be realized through the inhibition efficacy of the addiction inhibitors on the addiction behavioral phenotypes of the addiction nematodes in a high-throughput manner. Compared with the prior art, the medicine screening method of a traditional cell function system is abandoned, and medicine screening is carried out on the living animal behavioristics level in a brand new mode. Meanwhile, the advantages of easiness in large-scale culture, abundant behavioral modes and the like of the nematodes are utilized, and compared with expensive mammal feeding and experimental operation for drug screening, the method has higher cost performance, practical operability and high throughput.

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

The invention discloses an application of a DHA-RXR-PPAR signal channel in promotion of postoperative recovery of hysteromyoma after HIFU (high intensity focused ultrasound). Clinical sample metabolic spectrum analysis and in-vitro cell function experiments are combined, and research proves that the differential metabolite DHA drives macrophage metabolism reprogramming through an RXR-PPAR signal axis, so that the macrophage is promoted to be transformed into an anti-inflammatory and phagocytosis-promoting repair phenotype, the absorption and repair process of the HIFU postoperative hysteromyoma is accelerated, and the treatment effect of the HIFU postoperative hysteromyoma is improved. A new intervention target spot (RXR-PPAR gamma axis) and a new potential medicine are provided for HIFU (high intensity focused ultrasound) postoperative rehabilitation.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

This invention provides the principle and method for influencing cellular functional excitatory expression through misaligned distribution of acoustic wave frequencies, relating to the interdisciplinary field of biological signal processing. The principle and method for influencing cellular functional excitatory expression through misaligned distribution of acoustic wave frequencies includes the following steps: Step 1: Target cell pretreatment, selecting cells to be regulated, separating, purifying, and culturing to the logarithmic growth phase, adjusting the cell density to... 1×104‑1×106cells / cm2 The cells are placed in a biocompatible culture medium. The method of this invention significantly improves the specificity of regulation. Through a frequency-function specific matching mechanism, frequency groups targeting specific cellular functions are screened. Combined with a multidimensional orbital misalignment design to avoid frequency interference, each frequency precisely activates the corresponding signaling pathway. The single-function excitation expression level of cells is more than twice that of the traditional single-frequency method, and the non-specific functional excitation rate is reduced by more than 80%, while the efficiency of action is greatly improved.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

The invention relates to the technical field of biology, in particular to a red fluorescent protein mCrimsonX as well as a construction method and application thereof. The invention relates to a red fluorescent protein mCrimson X. The mutant amino acids of the red fluorescent protein mCrimson X relative to Crimson comprise N8E, R10P, M15L, S18T, I70V, Y72H, A74K, D75G, F79Y, T94M, Y96F, E111Q, E114V, V116I, V119A, M147I, I160M, N173S, T177E, H193Y and V195I. The invention further discloses a preparation method of the red fluorescent protein mCrimson X. The preparation method has the advantages that mCrimsonX is high-performance long-wavelength fluorescent protein in a visible region; special proteins which cannot be accurately marked by other red fluorescent proteins can be marked; the monomer property is very good, and the extinction coefficient and the quantum yield are relatively high. The method can be used for constructing cell function probes and is wide in application range.

An object of the present invention is to provide a novel screening technique for selecting a useful pharmaceutical compound.SOLUTION: The present invention for solving the above-mentioned problems is a method for screening an active ingredient of a medicament, comprising a step of topically administering a candidate substance to a region where a specific tissue develops in an embryo of an animal (excluding human) or the vicinity thereof, a step of observing the specific tissue or a differentiated cell of the specific tissue in the animal after the topical administration, and a step of selecting, as the active ingredient, a candidate substance observed to improve a function of the specific tissue or the differentiated cell as compared with the case where the candidate substance is not administered.SELECTED DRAWING: None

The invention belongs to the technical field of new applications of medicines, and particularly relates to an aniline pyridine TEAD degradation agent, a preparation method thereof and an application of the degradation agent in preparation of antitumor drugs. According to the research, a novel aniline pyridine TEAD degradation agent with a clear structure is designed and synthesized by coupling a TEAD palmitoylation inhibitor niflumic acid serving as a lead compound with a CRBN type E3 ligase ligand through connecting chains with different lengths and different types by virtue of a computer-aided drug design means. The influence of the optimal compound (XY-3L) on cancer cell proliferation and cell functions is detected in an in-vitro cell experiment, and the curative effect of the optimal compound (XY-3L) in a melanoma lung metastasis model is explored in vivo.

The invention discloses an application of a preparation for inhibiting the interaction of SPP1 / CD44 in preparing a medicine for preventing and / or treating nucleus pulposus cell degeneration, and relates to a method for effectively improving the nucleus pulposus cell function and degeneration by inhibiting the interaction of SPP1 / CD44 and inhibiting the nucleus pulposus cell degeneration induced by M1 macrophages. Potential intervention mechanisms and targets are provided for clinical prevention and treatment of the intervertebral disc degenerative diseases, and important research significance and clinical application prospects are achieved.

The invention relates to the technical field of biomedical processing, and particularly provides a cryopreservation method of cord blood mononuclear cells, which comprises six steps of whole blood separation, plasma inactivation, CBMC cell separation, cryopreservation liquid preparation, cell cryopreservation and detection after cryopreservation recovery. The CBMC cell separation comprises three sub-steps; performing cell cryopreservation, namely averagely dividing the separated CBMC into a plurality of parts, filling the CBMC into a cryopreservation tube according to a certain density, putting the cryopreservation tube into a programmed cooling instrument, and performing cryopreservation according to a plurality of programs; and detecting after cryopreservation and resuscitation, wherein the detection comprises three sub-steps of cell viability detection, cell recovery rate detection and cell function detection. The problems that in the cryopreservation process of a traditional method, cell viability is reduced, the number of cells is greatly reduced, cell adhesion and caking are caused, cell functions are abnormal, cell phenotypes are changed after recovery, functional activity is damaged and the like are solved, the utilization rate of the CBMC is increased, and the technical scheme is obviously superior to the traditional cell cryopreservation method; the viability, the recovery rate and the function of the recovered cells are obviously improved.

The application provides a tumor immune microenvironment multi-cell recognition and spatial analysis system, comprising: an intrinsic signal generation module generating an initial intrinsic signal vector; a preliminary functional marker module generating a preliminary phenotype classification label map based on spatial centroid coordinates of cell objects; a functional neighborhood construction module calculating and generating a functional neighborhood feature vector; a composite feature splicing module constructing a composite state feature vector; an effective function determination module decoding to obtain a continuous value feature vector output by a function determination model representing the final function strength under the regulation of the microenvironment; and a functional map rendering module rendering to generate a cell effective function map under the regulation of the environment. The application solves the problem that, in the prior art, when interpreting cell functions, the intrinsic state information of the cells and the local functional microenvironment context information cannot be effectively fused, resulting in deviation in the description of the spatial distribution map of tumor microenvironment function heterogeneity.

The invention provides a polypeptide for enhancing T cell function and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the polypeptide disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, an interaction interface of CLDN18.2 and beta-catenin is targeted for the first time, the full D-type functional polypeptide is designed to realize high-stability and high-affinity protein-protein interaction blocking, and the problem that the interaction site is difficult to target by the traditional antibody drug or small molecule drug is broken through; the used polypeptide PC18.1 has good in-vitro stability and is suitable for subsequent clinical development; the polypeptide is easy to prepare on a large scale through a synthesis means, has the purity of more than or equal to 98%, is low in cost and convenient to modify, and can be flexibly applied to immune combined treatment schemes such as nano-carrier loading and local delivery.

This application belongs to the field of biotechnology and relates to an efficient and specific editing system, method, and application for A-G base substitution. The fusion protein described in this application comprises, from the N-terminus to the C-terminus, a first SaCas9 nickase fragment, a chimeric deaminase fragment, and a second SaCas9 nickase fragment. The deaminase is selected from adenosine deaminase or a variant thereof, specifically ecTadA8e. The amino acid sequence of ecTadA8e is shown in SEQ ID NO. 20, or has more than 80% sequence identity with the amino acid sequence shown in SEQ ID NO. 20, and possesses the function or activity of ecTadA8e. The fusion protein provided in this application, combined with the corresponding guide RNA, can efficiently and specifically replace the base A with G at the target site, providing an effective tool for repairing pathogenic mutations, studying gene function, and improving cell function, and has promising application prospects.

A fusion protein comprises (1) a first moiety that targets and orients the fusion protein to mitochondria inner membrane and (2) a second moiety that provides light-activated proton pump function when integrate into the mitochondria inner membrane. The fusion protein can be used for modulating hypoxia signaling in a subject, revitalizing cells, modulating T cell function, improving feed efficiency, prolonging lifespan and treating cancer.

This invention discloses a GABA-loaded hydrogel microneedle, its preparation method, and its application, belonging to the field of biomedical materials technology. This drug-loading system uses polypyrrole-grafted gelatin (PPy) as the loading medium. ‑ Using gelatin (GelMA), carboxymethyl chitosan, and methacrylate gelatin (GelMA) as a matrix, a three-dimensional network hydrogel (PPG@Gel) is formed through cross-linking with aldehyde-modified polyethylene glycol (PEG-CHO) and loaded with γ-aminobutyric acid (GABA). The preparation process includes GelMA modification, PPy-GelMA graft polymerization, PEG-CHO cross-linking agent synthesis, and mixing of each component with GABA to form a precursor hydrogel (PPG@Gel), which can ultimately be prepared as a microneedle patch (PPG@MN). This invention utilizes the excellent biocompatibility and permeability of hydrogels to achieve precise local delivery of GABA to lesions in inflammatory skin diseases. GABA can target and inhibit abnormal inflammatory responses, regulate epidermal cell function, and repair the skin barrier, while avoiding the adverse reactions and cost drawbacks of existing treatments. The hydrogel raw materials are readily available and highly safe, allowing for continuous drug delivery to improve patient compliance. It is suitable for the treatment of various inflammatory skin diseases such as psoriasis and eczema, and has significant clinical application value.

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K6 site succinylation modification and application. Experiments show that the 6th lysine of the PGK1 protein has succinylation modification (PGK1 K6su), and the existence of the succinylation modification at the 6th lysine is confirmed through immunoprecipitation experiments; cell function experiments prove that the PGK1 K6su enhances lung cancer cell migration and multiplication capacity and promotes lung cancer progression. A small molecule compound diammonium glycyrrhizinate aiming at the PGK1 K6 site is further obtained through computer-assisted screening, and subsequent experiments find that the compound can inhibit proliferation and migration of lung cancer cells by reducing the succinylation modification level of the lung cancer cells PGK1 K6.

The invention discloses an application of a GABAA alpha 6 receptor knockout substance and a combined drug thereof in preparation of a bladder cancer treatment product. The invention provides an application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a tumor treatment product. The invention also provides application of a substance for knocking out the GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a product for inhibiting tumor progression. By knocking out the GABAA alpha6 receptor gene, the regulation effect of the GABAA alpha6 receptor gene on CD8 + T cell functions is researched, the application value of the GABAA alpha6 receptor gene in bladder cancer treatment is verified, and a new strategy is provided for clinical treatment.

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.